

Applicant : Donald W. Landry  
U.S. Serial No.: Not Yet Known  
Filed : August 28, 2001  
Page 2

In the claims:

Please cancel claims 2-20 and 22-40 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a later-filed application. Please also amend claims 41-48 under the provisions of 37 C.F.R. § 1.121(c) as follows. A marked up version of amended claim 41-48 wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit A:

- 0940727-08201  
FOR 2240660
- 41. (Amended) A nucleic acid which encodes the catalytic antibody of claim 1.--
- 42. (Amended) A nucleic acid which encodes the polypeptide of claim 21.--
- 43. (Amended) The catalytic antibody of claim 1, wherein the catalytic antibody is humanized.--
- 44. (Amended) The polypeptide of claim 21, wherein the polypeptide is humanized.--
- 45. (Amended) A pharmaceutical composition for decreasing the concentration of cocaine in a subject which comprises an amount of the antibody of claim 1 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.--
- 46. (Amended) A method of decreasing the concentration of cocaine in a subject which comprises administering to the

Applicant : Donald W. Landry  
U.S. Serial No.: Not Yet Known  
Filed : August 28, 2001  
Page 3

subject an amount of an the antibody of claim 1 effective to degrade cocaine in the subject, so as to thereby decrease the concentration of cocaine in the subject.--

--47. (Amended) A pharmaceutical composition for treating cocaine overdose in a subject which comprises an amount of the antibody of claim 1 effective to degrade cocaine in the subject and a pharmaceutical acceptable carrier.--

--48. (Amended) A method for treating cocaine overdose in a subject which comprises administering to the subject an amount of the antibody of claim 1 effective to degrade cocaine, so as to thereby treat cocaine overdose in the subject.--

In the abstract:

Please add new page 116 containing the abstract of the disclosure, attached hereto as **Exhibit B**.

**Remarks:**

Claims 1-48 are pending in the subject application. Applicants have herein canceled claims 2-20 and 22-40 without disclaimer or prejudice to their right to pursue the subject matter of these claims in a later-filed application. Applicants have also herein amended claims 41-48. Support for these amendments may be found inter alia in the specification on page 8, line 8-25. Applicants have also added new page 116 containing the abstract attached hereto as Exhibit B. This amendment does not involve any issue of new matter. Therefore, entry of this amendment is respectfully